De-escalation of Radiation in Positive Axilla for Breast Cancer Radiation de escalation breast cancer
Main Article Content
Abstract
Introduction: There has been a trend towards de-escalation in the management of axilla over the last two decades in the form of shift from axillary lymph node dissection to sentinel lymph node dissection in early stage breast cancer. This de-escalation has main advantage in terms of reducing the incidence of lymphedema without compromising the local control. However, when it comes to axillary radiation, there is lack of consensus regarding its use . In this context we reviewed our prospectively maintained data base for axillary recurrences, without radiation to axilla in axillary node positive patient cohort.
Materials and methods: The data of breast cancer patients treated at Medanta, Cancer Institute from 2010 till 2020 was analyzed by querying the electronic health records. Minimum follow up was 2 years after completion of radiation treatment. During follow up, patients were assessed clinically and underwent yearly mammogram, bi-annual ultrasound abdomen and annual chest X-Ray. In case of clinically palpable or suspicious lymph nodes in axilla, a histopathological confirmation was required. The axilla was not irradiated intentionally except in very few cases where the decision was individualized as per surgical and pathological findings after discussion in the tumour board meeting.
Results: Of the 2400 breast cancer patients treated from 2010-2020, final analysis included 1422 patients as per the inclusion criteria. Pathological node positive cases were 827(58.15%). Of which 446/827(53.9%) had N1, 283/827(34.2%) were N2 and 98/827(11.8%) were with N3 disease status. 69.19% patients had undergone axillary dissection. A total of 35 patients received axillary radiation, 7 of them had early stage disease, underwent sentinel lymph node biopsy and were treated before 2013, and rest of them had advanced local disease, post axillary dissection with high axillary burden and presence of high risk features. None (0%) of the patients developed ipsilateral axillary relapse.
Conclusion: The results of this study are a step further in de-escalation of axillary management in terms of radiation, and provide robust data in support of omitting the axillary radiation for breast cancer patients even when sentinel node biopsy shows (1-2) positive nodes for early stage breast disease and in locally advanced breast disease when adequate axillary dissection (even with heavy axillary node burden) has been performed.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Giordano, SH, Buzdar, AU, Smith, TL, et al. Is breast cancer survival improving? Cancer 2004;100: 44.
3. Demuyiwa FO, Groman A, Hong CC, et al. Time-trends in survival in young women with breast cancer in a SEER population-based study. Breast Cancer Res Treat. 2013;138: 241–8.
4. Goetz MP, Gradishar WJ, Anderson BO et al. NCCN Guidelines Insights: Breast Cancer, Version 3.2018.
5. Livsey JE, Magee B, Stewart AL, Swingdell R. Axillary recurrence following conservative surgery and radiotherapy in early breast cancer. Clin Oncol 2000;12:309-14.
6. Voogd AC, de Boer R, van der Sangen MJ, Roumen RM, Rutten HJ, Coebergh JW. Determinants of axillary recurrence after axillary lymph node dissection for invasive breast cancer. Eur J Surg Oncol. 2001 Apr;27(3):250-5.
doi: 10.1053/ejso.2000.1111
7. Bilimoria KY, Bentrem DJ, Hansen NM, et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol. 2009;27:2946–53.
8. Hwang RF, Gonzalez-Angulo AM, Yi M, et al. Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection. Cancer. 2007 Aug 15;110(4):723-30.
doi: 10.1002/cncr.22847.
9. Pugliese MS, Karam AK, Hsu M, et al. Predictors of completion axillary lymph node dissection in patients with immunohistochemical metastases to the sentinel lymph node in breast cancer. Ann Surg Oncol. 2010;17:1063–68.
10. Langer I, Guller U, Viehl CT, et al. Axillary lymph node dissection for sentinel lymph node micrometastses may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study. Ann Surg Oncol. 2009;16:3366–74.
11. Giuliano AE, Ballman KV, McCall L, et al. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA. 2017 Sep 12;318(10):918-26.
doi: 10.1001/jama.2017.11470.
12. Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014 Nov;15(12):1303-10. doi: 10.1016/S1470-2045(14)70460-7.
13. Kataria T, Bisht SS, Gupta D, et al. Incidental radiation to axilla in early breast cancer treated with intensity modulated tangents and comparison with conventional and 3D conformal tangents. Breast 2013; 22 6:1125–29.
14. Wright, F.C., Walker, J., Law, C.H.L. et al. Outcomes After Localized Axillary Node Recurrence in Breast Cancer. Ann Surg Oncol 10, 1054–1058 (2003). https://doi.org/10.1245/ASO.2003.01.017
15. Fredriksson I, Liljegren G, Arnesson LG, et al. Consequences of axillary recurrence after conservative breast surgery. Br J Surg. 2002 Jul;89(7):902-8.
doi: 10.1046/j.1365-2168.2002.02117.x.
16. Newman LA, Hunt KK, Buchholz T, Kuerer HM, Vlastos G, Mirza N, Ames FC, Ross MI, Singletary SE. Presentation, management and outcome of axillary recurrence from breast cancer. Am J Surg. 2000 Oct;180(4):252-6. doi: 10.1016/s0002-9610(00)00456-6.
17. Livsey JE, Magee B, Stewart AL, Swindell R. Axillary recurrence following conservative surgery and radiotherapy in early breast cancer. Clin Oncol (R Coll Radiol). 2000;12(5):309-14.
doi: 10.1053/clon.2000.9181.
18. de Boer R, Hillen HF, Roumen RM, Rutten HJ, van der Sangen MJ, Voogd AC. Detection, treatment and outcome of axillary recurrence after axillary clearance for invasive breast cancer. Br J Surg. 2001 Jan;88(1):118-22. doi: 10.1046/j.1365-2168.2001.01637.x
19. Langer I, Marti WR, Guller U, et al. Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases: prospective analysis of 150 patients after SLN biopsy. Ann Surg. 2005 Jan;241(1):152-8.
doi: 10.1097/01.sla.0000149305.23322.3c.
20. Konkin DE, Tyldesley S, Kennecke H, Speers CH, Olivotto IA, Davis N. Management and Outcomes of Isolated Axillary Node Recurrence in Breast Cancer. Arch Surg. 2006;141(9):867–874. doi:10.1001/archsurg.141.9.867.
21. Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014; 15(12): 1303–10.
22. Sávolt A, Musonda P, Mátrai Z, et al. Optimal treatment of the axilla after positive sentinel lymph node biopsy in early invasive breast cancer. Early results of the OTOASOR trial. Orv Hetil. 2013 Dec 8;154(49):1934-42. Hungarian. doi: 10.1556/OH.2013.29765.
23. Ling DC, Iarrobino NA, Champ CE, Soran A, Beriwal S. Regional Recurrence Rates With or Without Complete Axillary Dissection for Breast Cancer Patients with Node-Positive Disease on Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy. Adv Radiat Oncol. 2019 Sep 27;5(2):163-70. doi: 10.1016/j.adro.2019.09.006.
24. Jagsi R, Barlow WE, Woodward WA. et al. Radiotherapy Use and Incidence of Locoregional Recurrence in Patients With Favorable-Risk, Node-Positive Breast Cancer Enrolled in the SWOG S1007 Trial. JAMA Oncol. 2023 Aug 1;9(8):1083-89. doi: 10.1001/jamaoncol.2023.1984
25. Taylor C, Dodwell D, McGale P et al. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials. Lancet. 2023 Nov 3:S0140-6736(23)01082-6. doi: 10.1016/S0140-6736(23)01082-6. Epub ahead of print. PMID: 37931633.
26. Gradishar WJ, Moran MS, Abraham J et al. Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw2022;20(6):691-722.
doi: 10.6004/jnccn.2022.0030.
27. Brackstone M, Fulvia G. B, Perera EF, et al. Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline. Journal of Clinical Oncology 2021; 39:3056-82.
doi: 10.1200/JCO.21.00934.
28. Csaba Polgar, Kahan Z, Ivanov O et al. Radiotherapy of Breast Cancer—Professional Guideline 1st Central-Eastern European Professional Consensus Statement on Breast Cancer. Pathol Oncol Res. 2022 Jun 23;28:1610378.
doi: 10.3389/pore.2022.1610378